10 results about "Methylsulfonylmethane" patented technology

The invention provides an application of methylsulfonylmethane in preparation of a product for treating asthenospermia. The research of the invention finds that the sulfhydrylation modification level of ATP synthetase can be effectively changed by using methylsulfonylmethane as an active component, so that the intracellular energy metabolism state of sperms is regulated and controlled, and the motility of the sperms is further changed.

A formulation for treating xerostomia and alleviating the symptoms of dry mouth is provided. Formulations comprising a humectant (such as propylene glycol), a chelator (such as EDTA and its salts) and a transport enhancer (such as methylsulfonylmethane (MSM)) are provided.

Multi-component pharmaceutical compositions perform various functions and confer various benefits by providing methylsulfonylmethane (MSM), fructose diphosphate (FDP), and an herbal component or a nutritional component. Compositions adhering to that pattern have unique and beneficial properties. Such compositions contain only three active components, in order to avoid canceling the positive effects of such compositions when too many components are present. The present claims expand on the work patented in U.S. Pat. Nos. 9,682,048 B1, 10,166,267 B1, and 10,183,053 B1.

The invention discloses a pharmaceutical composition for preventing and treating joint inflammation / relieving pain and a preparation method thereof. The pharmaceutical composition comprises the following components: 1, glucosamine sulfate 2KCL (99%), 2, chondroitin sulfate, 3, methylsulfonylmethane (MSM), 4, type II collagen, 5, a morinda officinalis root extract, 6, a herba epimedii extract, 7, a sambucus williamsii extract, 8, a rhizoma drynariae extract, 9, a turmeric root extract, 10, hyaluronic acid and 11, chitosan. The pharmaceutical composition can be prepared into tablets, capsules, dispersible tablets, chewable tablets, effervescent tablets, buccal tablets and other oral preparations. The composition has the effect of preventing and relieving knee joint inflammation / pain.

The invention relates to an external transdermal enhanced gel composition for nursing joints of dogs and cats and a preparation method of the external transdermal enhanced gel composition, and belongs to the technical field of pet health care and health care. The gel composition comprises: a) 1.0-2.5% of a gel matrix, wherein the gel matrix comprises xanthan gum and gellan gum in a weight ratio of (3-1): 1; b) 6-20% of an active care component, wherein the active care component comprises a frankincense extract, glucosamine hydrochloride, low molecular weight chondroitin sulfate, menthol and methylsulfonylmethane; c) 7-20% of a transdermal enhancing component, the transdermal enhancing component comprises azone, propylene glycol and curcumin-loaded anion liposome dispersion liquid, the weight ratio of azone to propylene glycol is 1: (1.5-3), and the solid weight of the anion liposome accounts for 0.5-2.0% of the total weight of the gel composition. The composition has excellent transdermal performance, exact anti-inflammatory and analgesic effects and excellent pet nursing compliance.

A functional animal chew includes chewing material, the chewing material having a first side surface and a second side surface opposite to it; pore array, the pore array consisting of evenly distributed pores that pass through the first side surface and the second side surface, with a pore density of 4 to 40 per square centimeter; and one or more functional ingredients, retained in the pores of the pore array. The chewing material includes natural rawhide and / or synthetic rawhide; the functional ingredient includes methylsulfonylmethane, with a mass percentage not exceeding 4% in the animal chew per 100 grams. The animal chew can supplement organic sulfur for domestic pets and address the technical issue of poor skin and hair health due to imbalanced intake of functional elements in domestic pets.

Pharmaceutical compositions of alpha-lipoic acid and / or methylsulfonylmethane (MSM) and magnesium salts, useful for the treatment, prevention, or reduction of the severity of viral infections and / or skin diseases, are provided herein. Methods for preparing the pharmaceutical compositions and methods for using the pharmaceutical compositions in therapeutic treatments are also provided.

The invention provides an aqueous sodium-ion battery electrolyte as well as a preparation method and application thereof, and belongs to the technical field of electrochemical energy storage. The aqueous sodium-ion battery electrolyte provided by the invention comprises the following components: sodium salt, water, an organic cosolvent, an ether diluent, ethylene glycol dimethyl ether and methylsulfonylmethane, the concentration of the sodium salt is 1-8 mol / kg; the volume ratio of the water to the organic cosolvent is 1: (3-7); the volume ratio of the ether diluent to the organic cosolvent is (0.1-0.5): 1. The voltage window is widened by limiting the volume ratio of water to the organic cosolvent and the volume ratio of the ether diluent to the organic cosolvent; ethylene glycol dimethyl ether forms an SEI film which is more stable and lower in impedance, and the ethylene glycol dimethyl ether and the ether diluent have a synergistic effect, so that a local low-water-activity environment is created; methylsulfonylmethane is preferentially decomposed on the surface of the negative electrode, so that the electrochemical performance is improved.

An iron chelate preparation containing a chelating agent (such as EDTA and its salts) and methylsulfonylmethane (MSM) is provided. The preparation can be an immediately drinkable beverage, a hydration drip, or any liquid that can be administered systemically to a subject. Using the disclosed composition, a preparation and method for treating RNA viruses including SARS-CoV-2 are provided. A preparation and method for inhibiting ferroptosis and diseases and conditions affected by ferroptosis are provided. Diseases and conditions affected by ferroptosis include cancer, aging, inflammation, and the like.

A functional animal chew includes chewing material, the chewing material having a first side surface and a second side surface opposite to it; pore array, the pore array consisting of evenly distributed pores that pass through the first side surface and the second side surface, with a pore density of 4 to 40 per square centimeter; and one or more functional ingredients, retained in the pores of the pore array. The chewing material includes natural rawhide and / or synthetic rawhide; the functional ingredient includes methylsulfonylmethane, with a mass percentage not exceeding 4% in the animal chew per 100 grams. The animal chew can supplement organic sulfur for domestic pets and address the technical issue of poor skin and hair health due to imbalanced intake of functional elements in domestic pets.